Skip to main content

Government Funding Lapse
Because of a lapse in government funding, the information on this website may not be up to date, transactions submitted via the website may not be processed, and the agency may not be able to respond to inquiries until appropriations are enacted.

The NIH Clinical Center (the research hospital of NIH) is open. For more details about its operating status, please visit cc.nih.gov.

Updates regarding government operating status and resumption of normal operations can be found at opm.gov.

HPV L1 virus-like particles vaccine NBP615

A human papillomavirus (HPV) vaccine composed of purified virus-like particles (VLPs) comprised of major capsid (L1) proteins from HPV subtypes 6, 11, 16 and 18, that can potentially be used for active immunization against HPV types 6, 11, 16 and 18. Upon intramuscular (IM) administration, the HPV L1 VLPs vaccine NBP615 activates the immune system to produce antibodies against the HPV subtypes. This protects against HPV infection and HPV-related cancers.

Check for active clinical trials using this agent View this agent in the NCI Thesaurus

Synonym:	HPV L1 VLPs vaccine NBP615 HPV vaccine NBP615
Code name:	NBP 615 NBP-615 NBP615

HPV L1 virus-like particles vaccine NBP615

Search NCI's Drug Dictionary